Clinical Trial Update: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the atezolizumab-venetoclax-obinutuzumab combination in relapse/refractory lymphomas has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Follicular Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED